Cancer Research Meeting Calendar  Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 55, 557-561, February 1, 1995]
© 1995 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wu, X.
Right arrow Articles by Spitz, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wu, X.
Right arrow Articles by Spitz, M. R.

A Case-Control Study of Nonrandom Distribution of Bleomycin-induced Chromatid Breaks in Lymphocytes of Lung Cancer Cases1

Xifeng Wu2, T.C. Hsu, John F. Annegers, Christopher I. Amos, John J. Fueger and Margaret R. Spitz3

Departments of Cell Biology [X. W., T. C. H.] and Epidemiology [C. I. A., J. J. F., M. R. S.], The University of Texas M. D. Anderson Cancer Center, and The University of Texas School of Public Health [J. F. A.], Houston, Texas 77030

We used a case-control study design to determine the association between bleomycin-induced chromatid breaks and the risk of lung cancer in general and by specific histopathological types. Lymphocytes from primary blood cultures of 78 controls and 75 cases with 4 histopathological types of lung cancer were treated with 0.03 unit/ml bleomycin for 5 h, and the frequency of induced chromatid breakage and the locations of the breaks were determined in Q-banded preparations. After adjustment for their length, the larger chromosomes had more breaks than the smaller chromosomes in both cases and controls. The cases had significantly more breaks on chromosomes 4 and 5 than the controls did, with odds ratios (ORs) of 4.9 [95% confidence limits (CL), 2.0, 11.7] and 3.9 (95% CL, 1.6, 9.3), respectively. When the lung cancers were classified by histopathological type, adenocarcinomas had significantly more breaks on chromosomes 4 and 5, with ORs of 3.0 (95% CL, 1.0, 8.7) and 3.5 (95% CL, 1.2, 10.7), respectively. For squamous cell carcinoma, the ORs were significantly elevated for breaks on chromosomes 2, 4, and 5 with ORs of 3.5 (95% CL, 1.0, 11.7), 10.2 (95% CL, 2.5, 41.9), and 7.9 (95% CL, 1.9, 32.8). For small cell carcinoma, breaks on chromosomes 2 and 4 showed significantly increased ORs of 33.2 (95% CL, 2.2, 513.3) and 20.4 (95% CL, 1.7, 250.1), respectively. However, no specific chromatid breaks were detected in cases with large cell carcinoma. When the frequency of chromatid breaks at specific regions was calculated, breaks at 4p14, 4q27, 4q31, 5q21-q22, 5q31, and 5q33 were significantly more common in lung cancer cases than in controls. Lung cancer risk had a dose-response relationship with breaks on chromosomes 4 and 5. Cigarette smoking had a strong interaction with breaks on chromosomes 2, 4, and 5. The findings suggest that the susceptibility of particular chromosome loci to mutagenic damage may be a risk factor for specific types of lung cancer.

1 Supported by NIH Grant CA 55769 and by the John S. Dunn Foundation, Houston, TX.

2 In partial fulfilment of the requirements for the doctoral degree at The University of Texas School of Public Health.

3 To whom requests for reprints should be addressed, at Box 189, Department of Epidemiology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030.

Received 8/ 1/94. Accepted 12/ 1/94.




This article has been cited by other articles:


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
D. L. Chao, C. C. Maley, X. Wu, D. C. Farrow, P. C. Galipeau, C. A. Sanchez, T. G. Paulson, P. S. Rabinovitch, B. J. Reid, M. R. Spitz, et al.
Mutagen Sensitivity and Neoplastic Progression in Patients with Barrett's Esophagus: A Prospective Analysis.
Cancer Epidemiol. Biomarkers Prev., October 1, 2006; 15(10): 1935 - 1940.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
J. Lin, X. Zhang, and Y. Chen
Mutagen sensitivity as a susceptibility marker for endometriosis
Hum. Reprod., October 1, 2003; 18(10): 2052 - 2057.
[Abstract] [Full Text] [PDF]


Home page
MutagenesisHome page
G. Szekely, E. Remenar, M. Kasler, and S. Gundy
Does the bleomycin sensitivity assay express cancer phenotype?
Mutagenesis, January 1, 2003; 18(1): 59 - 63.
[Abstract] [Full Text] [PDF]


Home page
Postgrad. Med. J.Home page
L Shao, M Lai, and Q Huang
Mutagen sensitivity and p53 expression in colorectal cancer in China
Postgrad. Med. J., November 1, 2001; 77(913): 713 - 716.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
M. Berwick and P. Vineis
Markers of DNA Repair and Susceptibility to Cancer in Humans: an Epidemiologic Review
J Natl Cancer Inst, June 7, 2000; 92(11): 874 - 897.
[Abstract] [Full Text] [PDF]


Home page
Arch Otolaryngol Head Neck SurgHome page
J.-Y. Ko, L. T. Lui, T.-S. Sheen, P.-J. Lou, and M.-M. Hsu
Increased Mutagen Sensitivity in Patients With Head and Neck Cancer Is Less Pronounced in Patients With Nasopharyngeal Carcinoma
Arch Otolaryngol Head Neck Surg, May 1, 1998; 124(5): 578 - 581.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1995 by the American Association for Cancer Research.